who created retatrutide Retatrutide TRIUMPH-1 Results: 28% Weight

As of mid-2026, retatrutide is still moving through its Phase 3 trials and regulatory reviews

It found a significant reduction in the risk of several cancers among GLP1R agonist users compared to insulin users, but no clear benefit compared to metformin, and even a potential increased risk of kidney cancer [3]

doi: 10.1016/j.jemermed.2020.06.059 3 YuXZhangSZhangL

One was a 26week trial of liraglutide that found no drop in amyloid levels, but it did find the medication preserved brain glucose metabolism, which is considered a sign of good brain function

[7] Commonly observed adverse effects include transient injection-site discomfort, breast tenderness, nausea, fluid retention, and mild mood fluctuation, whereas rarer but serious events encompass venous or arterial thromboembolism, gallbladder disease, significant elevation of blood pressure, and hormone-sensitive malignancies such as endometrial or breast cancer